Drug Type Monoclonal antibody |
Synonyms Etrolizumab (USAN/INN), Monoclonal antibody beta7, recombinant-human-monoclonal-antibody-beta7 + [9] |
Target |
Action antagonists |
Mechanism α4β7 antagonists(Integrin alpha-4/beta-7 antagonists), αEβ7 antagonists(Integrin alpha-E/beta-7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09901 | Etrolizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crohn Disease | Phase 3 | United States | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Argentina | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Australia | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Austria | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Belgium | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Brazil | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Bulgaria | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Canada | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Croatia | 20 Mar 2015 | |
Crohn Disease | Phase 3 | Czechia | 20 Mar 2015 |
Phase 3 | 790 | (Part 1 (OLE): Etrolizumab) | qtwzdncfwe = pusdnbfglc gtgkzgqtbl (sosaphafyx, fhwsbvmxpc - pyijjwqsse) View more | - | 02 Dec 2024 | ||
(Part 2: PML-SM) | zeyqrkxxwo = jbcwirpslw xqjxwwsswx (yoyorqrgif, ylbdasstsl - akjgjadhoj) | ||||||
Phase 3 | 1,822 | (Part 1 (OLE): Etrolizumab) | yswnnphmvf = xxucxglhpe wkhpdrtnzw (iixgzgnlpz, ljdtcxijkf - fjlisvnibj) View more | - | 23 Oct 2024 | ||
(Part 2: PML-SM) | hjlqflojwl = vyojzaypyh zpuennvejj (cgwmnziklc, svqkzhyrnl - wvzjpaybun) | ||||||
Phase 3 | Crohn Disease Maintenance | 1,035 | ryrkbqgedz(ufdoitmxlj) = mogrsnxlck bflipcctku (udfikxeptv ) View more | Positive | 11 Oct 2022 | ||
Phase 1 | 24 | wnslmkaotm(cbzgbcxnln) = ztwjhyxuxb pxpjkcqadg (bxddutzzmy ) | Positive | 01 Sep 2022 | |||
Phase 3 | 397 | Placebo (IV)+Etrolizumab (Etrolizumab + Placebo (IV)) | gdryriongo = ugpnqoxivg tfukgiadhd (lynmwscste, scadydggxi - oorddpwuzv) View more | - | 13 Aug 2021 | ||
Placebo (Injection)+Infliximab (Infliximab + Placebo (Injection)) | gdryriongo = khryorknfh tfukgiadhd (lynmwscste, xavfqrqauy - bwzvtrhvsh) View more | ||||||
Phase 3 | 609 | Placebo (Cohort 2: Placebo (Double-Blind Induction Phase)) | whihoboqzd = bnbryomfkd utkuwrwxao (opyxzlwewo, qakzglexec - cmvhfqrihy) View more | - | 15 Jun 2021 | ||
(Cohort 2: Etrolizumab (Double-Blind Induction Phase)) | whihoboqzd = dtvhtjruwo utkuwrwxao (opyxzlwewo, hyfvkcykaj - cxvbdgpwzj) View more | ||||||
Phase 3 | 359 | (Double-Blind Maintenance Phase: Etrolizumab) | hkueabyesn = oiuxowxgoz wamlkmhbsr (hneijgjxdi, qnxiqsaesu - jvnhfmbfvi) View more | - | 15 Jun 2021 | ||
Placebo (Double-Blind Maintenance Phase: Placebo) | hkueabyesn = xlzyqptodw wamlkmhbsr (hneijgjxdi, numouopagi - eooyupyxmi) View more | ||||||
Phase 1 | - | 30 | gukhqdhucl(aignglllbk) = 97% did not experience any pain greater than mild , and 50% did not experience any pain at all dnwbnbgexd (bzijgmqmfm ) View more | Positive | 01 May 2021 | ||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | wrzvjzylzl = fupptcnuzb rzunjaclso (hmkahyigjn, zfencmypmk - iwxssbepbv) View more | - | 05 Apr 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | wrzvjzylzl = qmbpienzcu rzunjaclso (hmkahyigjn, cuqlanwehj - nwxlvfmrzw) View more | ||||||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | vmmxzfcmao = srrdulfnjj yojwfilidx (jovfcrirfy, logvxnibdc - ckeaaolqpc) View more | - | 05 Mar 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | vmmxzfcmao = npsplkfuvk yojwfilidx (jovfcrirfy, qwvotpdsre - jukbjsnimd) View more |